RT Journal Article
SR Electronic
T1 Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 956
OP 968
DO 10.1136/ijgc-2019-000499
VO 29
IS 5
A1 Emily Hinchcliff
A1 Shannon Neville Westin
A1 Graziela Dal Molin
A1 Christopher J LaFargue
A1 Robert L. Coleman
YR 2019
UL http://ijgc.bmj.com/content/29/5/956.abstract
AB The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food and Drug Administration approval since 2014. Given the rapidly expanding use of PARPi, this review aims to summarize the key evidence for their use and therapeutic indications. Furthermore, we provide an overview of the development of PARPi resistance and the emerging role of PARPi combination therapies, including those with anti-angiogenic and immunotherapeutic agents.